Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, announced on Friday that it has received clearance from the UAE Ministry of Health for its antiviral medication Oseltamivir BR Flu.
In a company press release, Abdulla Humaid Al Mazroei, vice-chairman, Neopharma, and Dr BR Shetty, managing director and CEO, thanked the UAE Ministry of Health on behalf of the company.
Dr Shetty said: “The endorsement for the antiviral drug manufactured by Neopharma, a local company, reflects the strong support of the Ministry of Health for the vision of the UAE leadership to create a self-sustaining community. As a leading manufacturer of life-saving drugs, we believe it is our responsibility to play a vital role in helping the community at this critical juncture.
“We are confident the approval for Oseltamivir will significantly facilitate medical professionals and the wider community to effectively tackle the lethal H1N1 virus in the region.”
Neopharma’s Oseltamivir BR Flu is the outcome of a joint venture with leading pharmaceuticals major Hetero Drugs Ltd and is the first in a series of major life-saving drugs the company plans to produce over the next few years in the region.
Neopharma at present has independent production blocks for the manufacture of general and betalactam products. The company’s plant in Abu Dhabi is designed for large-scale production of tablets, capsules and liquid orals.
Follow us on
